CD22 and acute lymphoblastic leukemia: Haso et al.302 reported that second-generation CAR-T cell immunotherapy was superior to third-generation CAR-T therapy with an anti-CD22 CAR in B-ALL, in contrast to the results of Ramos et al.’s research301.